报价延迟最少15分钟:2026/04/26 18:40 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.36 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.74/-0.12
|
|
企业价值
273.61M
|
| 资产负债 |
|
每股账面净值
1.18
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
77.36M
|
|
每股收益
1.53
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease. |
